中國奧園(03883.HK):集團的逾九成房地產項目按計劃及進度進行
格隆匯7月3日丨中國奧園(03883.HK)發佈公吿,2023年首六個月,集團的未經審核物業合同銷售額累計約人民幣74.8億元。於本公吿日期,集團的逾九成房地產項目按計劃及進度進行。集團繼續確保項目竣工交付,同時整合資源盤活項目的建設和銷售,降低營運開支,全力設法改善流動性。
公司已於2023年6月30日刊發所有尚未刊發的財務業績,包括2021年度業績、2022年中期業績及2022年度業績。2021年度報吿、2022年中期報吿及2022年度報吿(載有上市規則規定的所有資料)將於適時寄發。公司股份自2022年4月1日(星期五)上午九時正起於聯交所暫停買賣並將繼續暫停買賣直至進一步通知。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.